Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATINUM
NCT06115499Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Overall Response Rate up to 12 months and Overall Survival up to 5 years. Started Aug 2024; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06115499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115499.